IRLAB’s CFO Viktor Siewertz leaves the company for a new leading position

Gothenburg, Sweden, August 11, 2025 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announces that Viktor Siewertz has decided to leave his position as Chief Financial Officer to take a senior position in another company. He will step down as CFO on August 31, 2025.

IRLAB announces the outcome of the company’s rights issue

Last day of trading in subscription rights in IRLAB’s rights issue